SG11201903829PA - Melatonin mini-tablets and method of manufacturing the same - Google Patents

Melatonin mini-tablets and method of manufacturing the same

Info

Publication number
SG11201903829PA
SG11201903829PA SG11201903829PA SG11201903829PA SG11201903829PA SG 11201903829P A SG11201903829P A SG 11201903829PA SG 11201903829P A SG11201903829P A SG 11201903829PA SG 11201903829P A SG11201903829P A SG 11201903829PA SG 11201903829P A SG11201903829P A SG 11201903829PA
Authority
SG
Singapore
Prior art keywords
international
tablets
mini
neurim
tel aviv
Prior art date
Application number
SG11201903829PA
Other languages
English (en)
Inventor
Moshe Laudon
Nava Zisapel
Original Assignee
Neurim Pharma 1991
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57482481&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201903829P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurim Pharma 1991 filed Critical Neurim Pharma 1991
Publication of SG11201903829PA publication Critical patent/SG11201903829PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Anesthesiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11201903829PA 2016-10-31 2016-11-29 Melatonin mini-tablets and method of manufacturing the same SG11201903829PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662415014P 2016-10-31 2016-10-31
PCT/IB2016/057190 WO2018078429A1 (en) 2016-10-31 2016-11-29 Melatonin mini-tablets and method of manufacturing the same

Publications (1)

Publication Number Publication Date
SG11201903829PA true SG11201903829PA (en) 2019-05-30

Family

ID=57482481

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903829PA SG11201903829PA (en) 2016-10-31 2016-11-29 Melatonin mini-tablets and method of manufacturing the same

Country Status (25)

Country Link
US (2) US10722494B2 (enrdf_load_stackoverflow)
EP (3) EP4474012A3 (enrdf_load_stackoverflow)
JP (1) JP6830156B2 (enrdf_load_stackoverflow)
KR (1) KR102167190B1 (enrdf_load_stackoverflow)
CN (1) CN109922795B (enrdf_load_stackoverflow)
AU (5) AU2016426598C1 (enrdf_load_stackoverflow)
CA (1) CA3040027C (enrdf_load_stackoverflow)
CY (1) CY1123449T1 (enrdf_load_stackoverflow)
DK (2) DK3777842T3 (enrdf_load_stackoverflow)
ES (2) ES2828034T3 (enrdf_load_stackoverflow)
FI (1) FI3777842T3 (enrdf_load_stackoverflow)
HR (2) HRP20201722T1 (enrdf_load_stackoverflow)
HU (2) HUE051362T2 (enrdf_load_stackoverflow)
IL (1) IL262537B (enrdf_load_stackoverflow)
LT (2) LT3337462T (enrdf_load_stackoverflow)
MX (1) MX386987B (enrdf_load_stackoverflow)
NZ (1) NZ747702A (enrdf_load_stackoverflow)
PL (2) PL3777842T3 (enrdf_load_stackoverflow)
PT (2) PT3337462T (enrdf_load_stackoverflow)
RS (2) RS61024B1 (enrdf_load_stackoverflow)
SG (1) SG11201903829PA (enrdf_load_stackoverflow)
SI (2) SI3337462T1 (enrdf_load_stackoverflow)
SM (2) SMT202500046T1 (enrdf_load_stackoverflow)
TW (1) TWI787164B (enrdf_load_stackoverflow)
WO (1) WO2018078429A1 (enrdf_load_stackoverflow)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220125733A1 (en) * 2020-10-23 2022-04-28 Atoz Pharmaceuticals Pvt Ltd Nongranulated compressed tablets of mesalamine, and process of preparation thereof
KR20230017814A (ko) * 2020-10-26 2023-02-06 일동제약(주) 옥수수불검화추출물을 포함하는 소형화된 경구투여 제제의 제조방법 및 이에 따라 제조된 소형화 제제
CN120076789A (zh) 2022-10-14 2025-05-30 雀巢产品有限公司 缓释褪黑激素组合物

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4600723A (en) 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
ES2134789T3 (es) 1991-05-09 1999-10-16 Neurim Pharma 1991 Composiciones que contienen melatonina.
ATE141051T1 (de) 1992-04-07 1996-08-15 Neurim Pharma 1991 Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie
US5449683A (en) 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
WO1995003043A1 (en) * 1993-07-26 1995-02-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University Sustained release oral compositions containing melatonin
US6469044B1 (en) * 1995-02-01 2002-10-22 Neurim Pharmaceuticals (1991) Ltd. Method for treating patients suffering from drug dependencies which lead to plasma melationin deficiencies
JP4516159B2 (ja) * 1995-02-01 2010-08-04 ニューリム ファーマシューティカルズ（１９９１）リミテッド 薬物嗜癖患者の治療のためのメラトニンの使用
FR2762513B1 (fr) * 1997-04-23 2003-08-22 Permatec Pharma Ag Comprimes bioadhesifs
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
SK287508B6 (sk) * 2000-01-05 2010-12-07 Neurim Pharmaceuticals (1991) Ltd. Použitie a formulácia prípravku na liečbu rezistencie voči antihypertenzívam a podobných stavov
US6458384B2 (en) * 2000-02-23 2002-10-01 Impetus Ag Pharmaceutical with predetermined activity profile
IL144900A (en) 2001-08-14 2013-12-31 Neurim Pharma 1991 Melatonin and drugs containing it for use in the treatment of primary insomnia, and the manufacture of those drugs
IL149377A (en) 2002-04-28 2012-10-31 Neurim Pharma 1991 Pharmaceutical formulation comprising melatonin for the potentiation of the effect of hypnotic compounds
KR20030016215A (ko) * 2002-07-05 2003-02-26 뉴림 파머슈티칼스 (1991) 리미티드 항고혈압제에 대한 내성 및 관련 질환의 치료를 위한 방법및 제형
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
WO2005063297A2 (en) 2003-12-24 2005-07-14 Sepracor Inc. Melatonin combination therapy for improving sleep quality
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
DE102006006532B4 (de) 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
WO2008148015A1 (en) 2007-05-24 2008-12-04 The Trustees Of Columbia University In The City Of New York Sustained release formulation of melatonin
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
US8691275B2 (en) 2011-01-28 2014-04-08 Zx Pharma, Llc Controlled-release melatonin compositions and related methods
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
DK2949322T3 (en) 2014-05-28 2018-07-23 Valpharma S P A FORMULATION FOR ORAL ADMINISTRATION COMPREHENSIVE MELATONIN IN STABLE FORM AND PROCEDURE FOR PREPARING THEREOF

Also Published As

Publication number Publication date
DK3337462T3 (da) 2020-10-12
LT3337462T (lt) 2021-01-11
IL262537A (en) 2018-12-31
CN109922795B (zh) 2021-10-08
AU2023202003A1 (en) 2023-05-04
EP3337462B1 (en) 2020-09-30
NZ782840A (en) 2025-02-28
CA3040027C (en) 2023-08-15
MX2019004736A (es) 2019-06-17
ES2828034T3 (es) 2021-05-25
SI3337462T1 (sl) 2021-01-29
SI3777842T1 (sl) 2025-03-31
EP4474012A2 (en) 2024-12-11
FI3777842T3 (fi) 2025-02-11
HRP20201722T1 (hr) 2021-03-05
EP3777842B1 (en) 2024-12-11
HRP20250166T1 (hr) 2025-05-09
AU2019101470B4 (en) 2020-06-25
PL3337462T3 (pl) 2021-01-25
SMT202500046T1 (it) 2025-03-12
EP4474012A3 (en) 2025-03-12
RS61024B1 (sr) 2020-12-31
ES3009413T3 (en) 2025-03-26
DK3777842T3 (da) 2025-02-03
AU2019200479B2 (en) 2020-10-22
AU2019200479A1 (en) 2019-02-14
EP3777842A1 (en) 2021-02-17
JP2019533672A (ja) 2019-11-21
AU2016426598A1 (en) 2018-05-17
US10869857B2 (en) 2020-12-22
LT3777842T (lt) 2025-04-10
PL3777842T3 (pl) 2025-05-12
AU2016426598B2 (en) 2018-11-01
KR102167190B1 (ko) 2020-10-19
PT3777842T (pt) 2025-02-11
KR20190014512A (ko) 2019-02-12
SMT202000575T1 (it) 2021-01-05
WO2018078429A1 (en) 2018-05-03
CN109922795A (zh) 2019-06-21
US20190060277A1 (en) 2019-02-28
US20200306227A1 (en) 2020-10-01
HUE070190T2 (hu) 2025-05-28
TW201817418A (zh) 2018-05-16
AU2016426598C1 (en) 2024-02-08
HUE051362T2 (hu) 2021-03-01
CA3040027A1 (en) 2018-05-03
AU2019101470A4 (en) 2020-01-16
NZ747702A (en) 2022-08-26
TWI787164B (zh) 2022-12-21
PT3337462T (pt) 2020-10-30
IL262537B (en) 2021-03-25
JP6830156B2 (ja) 2021-02-17
MX386987B (es) 2025-03-19
EP3337462A1 (en) 2018-06-27
RS66471B1 (sr) 2025-03-31
US10722494B2 (en) 2020-07-28
CY1123449T1 (el) 2022-03-24
AU2021200268A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201907034PA (en) Methods of treating influenza
SG11201807913XA (en) Stabilized soluble pre-fusion rsv f proteins
SG11201811491YA (en) Quinazoline and indole compounds to treat medical disorders
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901534VA (en) Combination therapy with controlled-release cnp agonists
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808713YA (en) Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201810801QA (en) Brain delivery protein
SG11201810078PA (en) Stabilized pre-fusion rsv f proteins
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide